Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.57 ^USD	+1.95%		-3.68%	-5.99%

Apr. 08	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	CI
Mar. 28	Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	MT

Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 07:28 am EDT

Milestone Pharmaceuticals Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 16.04 million compared to USD 16.65 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.39 a year ago.
For the six months, sales was USD 1 million. Net loss was USD 30.99 million compared to USD 30.66 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.73 a year ago.

Latest news about Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	Apr. 08	CI
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	Mar. 28	MT
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	Mar. 28	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating	Mar. 05	MT
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA	Feb. 26	DJ
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt	Feb. 26	CI
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating	Dec. 27	MT
Milestone Pharmaceuticals Says FDA Issued Refusal-to-File Letter for New Drug Application for Etripamil; Shares Fall Pre-Bell	Dec. 26	MT
Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	Dec. 26	DJ
Top Premarket Decliners	Dec. 26	MT
Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	Dec. 26	DJ
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT	Dec. 26	CI
Transcript : Milestone Pharmaceuticals Inc. - Shareholder/Analyst Call	Nov. 13
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Alta Advisers Sends a Letter to Milestone Pharmaceuticals	Nov. 09	CI
Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil	23-10-24	CI
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating	23-08-11	MT
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Top Premarket Decliners	23-07-20	MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy	23-06-20	MT
Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet	23-06-20	CI
Transcript : Milestone Pharmaceuticals Inc. - Special Call	23-05-22
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

Chart Milestone Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.57 USD

Average target price

10.5 USD

Spread / Average Target

+568.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MILESTONE PHARMACEUTICALS INC.	-5.99%	96.6M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs